Debio 1124 / Paul Scherrer Institute - LARVOL DELTA

Results of the phase I "Lumed " study: Dose escalation of 177Lu-PP-F11N in patients with medullary thyroid carcinoma. (EANM 2024) - P1 | "Depending on the escalation cohort, patients received up to 4 infusions of 177Lu-PPF11N in an interval of 8-10 weeks... In the two escalation cohorts with 3 x 6 GBq and 4 x 8 GBq 177Lu-PP-F11N, no patient suffered any dose limiting toxicity. Therefore, activity doses of at least 4 x 8 GBq 177Lu-PP-F11N can be considered as a safe activity dose in future therapy trials or in clinical application."

Clinical • P1 data • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CCKBR

Debiopharm's New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer (PRNewswire) - "Debiopharm...today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study assessing the safety, distribution, and dosing of Debio 1124 in patients with advanced, unresectable pulmonary and extrapulmonary small cell carcinoma."

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer